Synonyms: GSK-2140944 | GSK2140944
Compound class:
Synthetic organic
Comment: Gepotidacin (formerly GSK2140944) is a novel, first-in-class, triazaacenaphthylene antibacterial that inhibits bacterial DNA gyrase and topoisomerase IV via a unique mechanism [2-3]. It was developed for potential to treat conventional and biothreat pathogens including MRSA, respiratory tract infections, acute bacterial skin and skin structure infections (ABSSI) [6], and uncomplicated urogenital gonorrhea [5].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Gepotidacin has advanced to Phase 3 clinical evaluation (last updated June, 2022). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04010539 | A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea | Phase 3 Interventional | GlaxoSmithKline | ||
NCT04187144 | Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI) | Phase 3 Interventional | GlaxoSmithKline | 7 | |
NCT04020341 | A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI) | Phase 3 Interventional | GlaxoSmithKline | 7 |